Krystal Biotech (NASDAQ:KRYS) Sets New 12-Month High – Should You Buy?

Krystal Biotech, Inc. (NASDAQ:KRYS)’s stock price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $221.97 and last traded at $222.6410, with a volume of 206466 shares trading hands. The stock had previously closed at $217.46.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Chardan Capital upped their target price on Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Citigroup increased their price target on Krystal Biotech from $166.00 to $198.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Bank of America lifted their price objective on shares of Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a research note on Friday, October 17th. HC Wainwright reissued a “buy” rating and set a $240.00 target price on shares of Krystal Biotech in a research note on Monday, September 15th. Finally, Guggenheim set a $224.00 price target on shares of Krystal Biotech and gave the stock a “buy” rating in a report on Friday, October 17th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $228.14.

Krystal Biotech Stock Up 5.5%

The business has a 50-day moving average price of $197.92 and a two-hundred day moving average price of $162.51. The company has a market capitalization of $6.79 billion, a price-to-earnings ratio of 35.10 and a beta of 0.48.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 3rd. The company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The business had revenue of $97.80 million during the quarter, compared to analyst estimates of $93.72 million. On average, sell-side analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the transaction, the insider owned 1,413,711 shares of the company’s stock, valued at approximately $311,242,613.76. This trade represents a 1.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently modified their holdings of the business. Soleus Capital Management L.P. raised its stake in shares of Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after purchasing an additional 481,200 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Krystal Biotech by 173.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after buying an additional 365,304 shares during the period. Braidwell LP increased its holdings in Krystal Biotech by 81.6% during the second quarter. Braidwell LP now owns 727,811 shares of the company’s stock worth $100,045,000 after buying an additional 327,067 shares during the last quarter. Norges Bank bought a new stake in Krystal Biotech in the second quarter worth about $38,861,000. Finally, Nuveen LLC purchased a new position in Krystal Biotech in the first quarter valued at about $42,223,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).